Biogen adds real-world test for Aduhelm to its confirmatory trial
Biogen and partner Eisai have said they will run a large-scale observational study of Alzheimer’s drug Aduhelm in the US to build evidence for the drug’s efficacy following its controversial approval. The ICARE AD-US study will provide information on the long-term effectiveness and safety of Aduhelm (aducanumab) as prescribed in routine clinical practice within the …
Biogen adds real-world test for Aduhelm to its confirmatory trial Read More »